

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 17, 2025

Humacyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-39532
(Commission File Number)

85-1763759
(I.R.S. Employer
Identification Number)

2525 East North Carolina Highway 54
Durham, NC
(Address of principal executive offices)

27713
(Zip code)

(919) 313-9633
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	HUMA	The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of \$11.50	HUMAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On April 17, 2025, Humacyte, Inc. issued a statement, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number	Description
99.1	Humacyte Statement on Recent Attacks, dated April 17, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMACYTE, INC.

By: /s/ Dale A. Sander

Date: April 17, 2025

Name: Dale A. Sander
Title: Chief Financial Officer, Chief Corporate Development
Officer and Treasurer



Humacyte Statement on Recent Attacks

DURHAM, N.C., April 17, 2025 – Dr. Laura Niklason, President and CEO of Humacyte, Inc. (Nasdaq: HUMA), released the following statement today:

“At Humacyte, we’re in the business of saving lives and limbs. The authors of a recent ‘citizen petition’ to the FDA – four men who have never used our product – want to stop us. We won’t let them succeed.”

“One of the signatories of this petition, Hooman Noorchashm, has filed nine previous petitions with the FDA, none of which has resulted in agency action. Another signatory, our chief critic, Robert E. Lee, left the FDA last fall – several months before Symvess was approved – to found Echelon, a private consulting firm focused on providing services to medical device companies. Two of Dr. Lee’s colleagues on the leadership team at Echelon also serve as key advisors to Phraxis, Inc., one of Humacyte’s potential competitors in providing vascular access for hemodialysis.”

“It’s perhaps no surprise that someone with competitive interests would resort to libel and slander against Humacyte. However, I hope that media outlets engaging with Dr. Lee disclose his clear and disqualifying personal conflicts of interest to their readers, rather than treating him as a credible voice.”

“The ‘citizen petition’ itself is without merit. We will respond at the appropriate time with the FDA.”

“Over the last two decades, we’ve worked hard to build Humacyte into what it is today. I take immense pride in that work, and I won’t let false, harmful claims go unchallenged.”